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Objective: Early life seizures (ELS) are often associated with cognitive and psychiatric 
comorbidities that are detrimental to quality of life. In a rat model of ELS, we explored 
long-term cognitive outcomes in adult rats. Using ACTH, an endogeneous HPA-axis 
hormone given to children with severe epilepsy, we sought to prevent cognitive deficits. 
Through comparisons with dexamethasone, we sought to dissociate the corticosteroid 
effects of ACTH from other potential mechanisms of action.
results: Although rats with a history of ELS were able to acquire a conditioned fear 
learning paradigm and controls, these rats had significant deficits in their ability to 
extinguish fearful memories. ACTH treatment did not alter any seizure parameters but 
nevertheless was able to significantly improve this fear extinction, while dexamethasone 
treatment during the same period did not. This ACTH effect was specific for fear extinc-
tion deficits and not for spatial learning deficits in a water maze. Additionally, ACTH did 
not alter seizure latency or duration suggesting that cognitive and seizure outcomes 
may be dissociable. Expression levels of melanocortin receptors, which bind ACTH, 
were found to be significantly lower in animals that had experienced ELS than in control 
animals, potentially implicating central melanocortin receptor dysregulation in the effects 
of ELS, and suggesting a mechanism of action for ACTH.
interpretation: Taken together, these data suggest that early treatment with ACTH can 
have significant long-term consequences for cognition in animals with a history of ELS 
independently of seizure cessation and may act in part through a CNS melanocortin 
receptor pathway.
Keywords: epilepsy, cognition, development, prefrontal cortex, melanocortins, acTh
inTrODUcTiOn
Psychiatric comorbidities and cognitive deficits are common in pediatric epilepsy. Children with 
epilepsy are at increased risk for depression, obsessive–compulsive disorder, anxiety, ADHD, autism, 
significant difficulty with learning and memory, and other disorders that indicated frontal lobe 
dysfunction (1–3). These comorbidities severely impact quality of life, often more than the seizures 
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themselves (4, 5). Understanding the nature of these deficits and 
finding effective treatment strategies is paramount.
We have previously shown that early life seizures (ELS) are 
associated with cognitive deficits. These deficits are often explored 
in the realm of hippocampal cognition (6, 7). More recently, we 
have also shown deficits in prefrontal cognition (8), which mirror 
deficits seen in children with epilepsy. Using both hippocampal- 
and prefrontal-dependent cognitive tasks [a water maze and a 
fear learning and extinction task that is associated with anxiety 
phenotypes in humans and animal models (9), respectively], we 
sought to understand the long-term effects of early treatment 
with ACTH and the corticosteroid dexamethasone on these 
aspects of cognition.
ACTH is used clinically for the treatment of infantile spasms. 
It reduces seizure frequency and may also have a positive impact 
of cognitive outcomes (10–14). This raises the possibility that 
ACTH could also be beneficial in other epilepsies associated with 
cognitive impairments. We have recently shown that ACTH is 
effective in ameliorating attention deficits associated with early 
life epileptiform activity and no seizures (15), but it remains 
uncertain whether ACTH could modify cognitive outcomes in 
the context of overt seizure activity that are not infantile spasms. 
Using an ELS model instead of an infantile spasms model allows 
us to explore the generalizability of ACTH treatment for other 
forms of pediatric epilepsy. We hypothesized that animals with 
a history of ELS would have significant deficits in fear condi-
tioning and spatial cognition, and that ACTH administration 
during the time of the seizures would prevent these deficits. 
Dexamethasone is also used to treat some severe epilepsies in 
children (16). Dexamethasone and ACTH are often considered 
together as hormonal therapies given that a possible mechanism 
of action of ACTH is via stimulation of melanocortin 2 recep-
tors in the adrenal with consequent release of corticosterone. 
However, if ACTH and dexamethasone are not similar in their 
effect on cognition associated with epilepsy, then it is possible 
that ACTH has mechanisms of action beyond stimulation of the 
adrenal.
MC2R is found solely in adrenal cortex, but all of the members 
of the melanocortin family of receptors bind ACTH with varying 
degrees of specificity. Two of these receptors, MC3R and MC4R, 
are expressed in the CNS, and therefore ACTH likely has direct 
CNS action in addition to its action on the adrenal. Recently, 
MC4R agonists have been used in animal models of Alzheimer’s 
disease and stroke as neuroprotective compounds that can also 
improve cognitive and behavioral outcomes (17–20). Although 
MC3R and MC4R agonism has been a suggested potential 
mechanism of action for ACTH in the treatment of seizures in 
infantile spasms (21), the role of the melanocortin system in 
cognitive impairment after ELS has yet to be explored. As such, 
the final aim of this study was to quantify expression of MCRs 
in the PFC and the hippocampus after ELS in order to begin to 
understand whether or not there is dysregulation of this receptor 
signaling pathway in our model.
The results show that ELS impairs PFC- and hippocampal-
dependent cognition. Early administration of ACTH, but not 
dexamethasone, can prevent PFC-dependent cognitive impair-
ment, suggesting dysregulation of central MCRs after ELS. 
Further supporting this hypothesis, MCRs are significantly 
downregulated in the PFC acutely after ELS. Importantly, this 
prevention occurs in the context of unchanged seizure outcomes.
MaTerials anD MeThODs
animals
All experiments were performed in accordance with the guide-
lines set down by the National Institutes of Health and the Geisel 
School of Medicine at Dartmouth for the humane treatment of 
animals. The animal protocol was approved by the Institutional 
Animal Care and Use Committee of Dartmouth College and the 
Institutional Animal Care and Use Committee of the University 
of Vermont.
early life seizure Model
Sprague-Dawley rats were subjected to a total of 62–65 flurothyl-
induced seizures from postnatal day (p) 7 to p16. ELS rats and 
littermate controls were separated into three groups; vehicle 
treated, ACTH treated, and dexamethasone treated (N  =  12 
ACTH  +  gelatin vehicle, N  =  14 dexamethasone  +  saline 
vehicle). Each rat received six to seven seizures per day and 
was allowed to recover for 1 h between seizures. Rat pups were 
placed into a sealed plastic container where 0.1 mL of flurothyl, 
an inhaled convulsive agent, was slowly dripped onto a small 
piece of filter paper within the chamber. Pups were observed 
carefully, and the chamber was unsealed and allowed to ventilate 
once animals showed signs of tonic forelimb and hindlimb 
extension. Littermate control pups were removed from the dam 
and handled at this time to control for the effect of handling- and 
maternal separation-related stress.
For experiments in which the effect of ACTH and dexametha-
sone on seizure latency and duration was examined, latency 
to seizure was observed in paired animals simultaneously to 
control for any discrepancy in injection volume and/or speed. 
Twenty-three rat pups (N = 9 ACTH, N = 10 vehicle, and N = 4 
dexamethasone) were exposed to flurothyl in tandem (paired 
randomly together in the chamber). Latency to initial tonic fore-
limb extension and duration of seizure was timed in each animal. 
In this cohort of animals, only one seizure was administered per 
day for 5 days from p6 to p10 in order to assess changes in latency 
and duration over time.
Drug administration
For the ACTH fear learning/extinction task, ELS and littermate 
control animals were injected subcutaneously with 150  IU/m2 
ACTH or the same dose of gelatin vehicle control, as previously 
described (10). Injections were made once daily, 1 h before ELS.
For the dexamethasone fear learning/extinction task, ELS and 
littermate control animals were injected subcutaneously with 
0.5 mg/kg dexamethasone or the same volume of saline vehicle 
control. Injections were made once daily, 1 h before ELS.
The ELS paradigm was the same for both groups of rats. A 
subset of the animals was weighed at the time of behavior; adult 
weights do not differ as a function of treatment (p = 0.12 for ACTH 
treatment and p = 0.20 for dexamethasone treatment). Mortality 
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in our study was low and unrelated to seizures or  treatment in 
the majority of animals; only two vehicle-treated ELS animals, 
one ACTH-treated, and one dexamethasone-treated animal died 
during the seizure period.
Water Maze
Animals were allowed to acclimate to the water maze room for 
1 h before any testing began. Water maze was conducted in a large 
(2 m in diameter by 50 cm in height) tub filled with opaque water 
maintained at approximately 26°C. The room housing the water 
maze contained two distal cues placed on a black cloth  covering 
the walls, approximately 50 cm away from the edge of the water 
maze. Indirect lighting was provided near the base of the water 
maze. On day 1, animals were allowed to habituate to the water and 
swim freely for 1 min without any platform present. A submerged 
platform was then introduced into the tub and testing began. Rats 
were placed tail-first into the water from four different starting 
locations selected randomly. Latency to find the platform was 
timed for four trials per day over the course of 4 days.
Fear learning acquisition and analysis
An operant box (Med Associates Inc., St. Albans, VT, USA) 
enclosed in a dimly lit, sound-attenuating chamber with a 
metal-bar floor was used for fear conditioning experiments. Rats 
were trained in a standard fear conditioning task. On day 1, all 
animals were habituated to the room and then the operant box 
where fear conditioning was to take place. On days 2 and 3, fear 
learning commenced. Each trial consisted of two 10 s presenta-
tions of a tone followed immediately by a 1-s, 0.75 mA footshock 
(inter-trial interval 64 s). There were three trials per session, one 
session per day. Behavior was recorded with a video camera and 
analyzed offline. For analysis, the instantaneous state of the rat 
was scored at 2, 10, 18, 26, 34, 42, 50, and 58 s after the second 
tone; 1 for moving and 0 for freezing (immobility with the excep-
tion of breathing). Freezing or moving scores were also collected 
during a 3-min pre-tone baseline in the operant chamber where 
the testing took place prior to administration of any tone or 
footshock.
Fear extinction
Fear extinction trials began 24 h after the second session of fear 
learning. For extinction, rats were placed in the same operant 
box, and the conditioned stimulus tone was played 30 times for 
10 s. Behavior was recorded with a video camera and analyzed 
offline. Moving behavior at 2, 6, 8, and 10 s after the beginning of 
the tone was scored and averaged to give one value per tone; 1 for 
moving and 0 for freezing at each of those time points. Freezing 
was defined as complete immobility with rigid body posture.
immunohistochemistry and cell counting
Early life seizures animals (N = 8 control, N = 9 ELS) were eutha-
nized at p19, 36 h after the ELS paradigm had ended. Animals 
were deeply anesthetized with isoflurane (4–5% in oxygen) until 
breathing slowed, and rats were unresponsive to a tail and paw 
pinch. Animals were then perfused transcardially with approxi-
mately 20 mL of PBS followed by 30 mL of 4% paraformaldehyde. 
Brains were then post-fixed in 4% paraformaldehyde overnight 
(18 h) and transferred to 30% sucrose until the point of sinking 
(2–3  days). Brains were placed in optimal cutting temperature 
(OCT solution) and flash-frozen at −80°C. Coronal sections 
through the infralimbic cortex and dorsal hippocampus were cut 
on a −25°C cryostat at 30 μm and placed into a 24-well plate 
containing 1 mL wells of PBS.
Endogenous peroxidase activity was then blocked with 1 mL 
3% hydrogen peroxide for 5 min, followed by three 5-min washes 
in PBS. Non-specific antigen binding was blocked by 600 μL of 
1% BSA, 3% normal goat serum, and 0.25% Triton X-100 in 
PBS for 30 min on a rocker. The sections were then incubated 
with 400 μL of either 1:400 rabbit Anti-Melanocortin Receptor 
3 (extracellular) or 1:700 rabbit Anti-Melanocortin Receptor 
4  (extracellular) antibodies (Alomone Labs, Jerusalem, Israel) 
at 4°C overnight (18 h) on a rocker. This was followed by three 
5-min washes in PBS, followed by incubation with 400 μL 1:1000 
Biotinylated Goat Anti-Rabbit IgG Antibody (Vector Labs, 
Burlingame, CA, USA) for 75 min at 25°C on a rocker. Five hun-
dred microliters of ABC avidin–biotin solution (Vector Labs) 
were then added to wells, and the plate was placed on a rocker 
for 30 min. Sections were washed three times with PBS, before 
400 μL of DAB–peroxidase substrate (Vector Labs) was added 
and left for 2–4 min. Sections were washed three times in PBS, 
then mounted onto charged slides, and dehydrated sequentially 
in baths of 70, 95, and 100% ethanol for 5 min each. Sections 
were cleared in methyl salicylate for 5 min, before coverslips were 
mounted using toluene-based mounting medium, and sealed 
with clear nail polish.
For cell counting, we used a microscope with Koehler illumi-
nation at 20× magnification to count cells in layers 2–3, 5, and 6 
of the infralimbic cortex, and in the CA1 pyramidal cell layer of 
the hippocampus. About 20× magnification was used because it 
allowed for identification of individual cells and the decreased 
zoom allowed for use of a larger defined counting frame. Eight 
coronal sections from each brain region were taken from each 
rat and stained according to the above method: four with MC3R 
antibody and four with MC4R antibody. Collection for PFC 
began based on visually identified corpus callosum landmarks at 
coordinates +3.5 mm to +2.9 mm anterior to bregma. Collection 
for hippocampal sections began based on ventricular and cornu 
amonnis landmarks at coordinates −2.8 to −4.0 mm posterior to 
bregma. Every third PFC section and every sixth hippocampal 
section were collected and stained. We used the optical fractiona-
tor function of Stereo Investigator (MBF Bioscience, Williston, 
VT, USA), with unbiased counting frames of 50 μm × 50 μm in 
the PFC and 25 μm × 25 μm in the hippocampus and grid sizes 
of 200 μm × 200 μm and 100 μm × 100 μm, respectively. The 
optical fraction was set at 10 μm depth, centered in the middle of 
the tissue section encompassed by the counting frame. The opti-
cal fraction was realigned for every new counting frame. Only 
cell tops falling within the optical fraction were counted. Cells 
touching the red line of the counting frame were discounted, 
whereas those touching the green line were included in the 
count. A total of 1210 control and 1238 ELS cells were counted 
in CA1 over an average volume of 1,990,302.6 ± 164,005.6 μm3 
in controls and 1,773,171.4 ±  101,309.4 μm3 in ELS animals; 
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a total of 16,833 control and 8193 ELS cells were counted in 
mPFC over an average volume of 5,062,576.6 ± 188,003.2 μm3 in 
controls and 3,605,728.1 ± 133,541.2 μm3 in ELS animals. Cells 
were counted blindly to reduce subjective bias. To eliminate bias 
due to area and thickness of tissue, cell counts were divided by 
volume of the section to obtain the more representative measure 
of cell density.
statistics
All fear learning and extinction data and cell staining counts 
were modeled using generalized estimating equations (GEE) in 
SPSS v22 (IBM corporation, Chicago, IL, USA) in order to ensure 
that the most appropriate data distribution was assumed and in 
order to deal with repeated measures. For the behavioral data, 
the dependent variable was moving score. For the immunohis-
tochemistry (IHC) data, the dependent variable was number 
of cells stained per volume of tissue. Group was modeled as a 
factor, with tone number as a covariate in the behavioral data. 
Fear extinction moving scores were best modeled as a linear scale 
response, whereas fear learning scores were modeled assuming a 
binomial distribution. In order to understand how the learning 
differed between the groups, all data were examined as group 
by tone effects and therefore describe mean differences between 
groups in the rate of learning as a function of tone. For extinction 
data where differences in the 30th (final) tone were reported, a 
one-way ANOVA using a Tukey post hoc test was used. Seizure 
duration and latency were also modeled using a GEE assuming a 
gamma distribution. Treatment (ACTH or vehicle) was used as a 
factor with day as a covariate.
Morris water maze data were analyzed using a multivari-
able Cox regression time-to-event approach in STATA (SEv13, 
StataCorp, TX, USA), as previously described (22, 23). Traditional 
analyses used to analyze water maze data have been questioned 
and time-to-event analyses are considered to be more appropri-
ate. Specifically, Jahn-Eimermacher et  al. argue against the use 
of ANOVAs, etc., in lieu of survival analysis for water maze and 
other behavioral data (24). Frailty Cox models were applied to 
deal with repeated measures over day. In addition to being the 
most appropriate way to analyze water maze data, this approach 
also allowed us to investigate the interaction between ELS and 
ACTH treatment while accounting for within-animal correla-
tions. The time-to-event was the latency (in seconds) to find the 
platform.
All values are reported as estimated marginal means ± SEM.
resUlTs
els cause significant Deficits in Fear 
extinction but not Fear learning
We first tested the effect of ELS on fear learning acquisition and 
subsequently fear extinction, two prefrontal-dependent tasks. 
No significant alterations in fear learning were noted in vehicle-
treated animals experiencing ELS (N = 8) compared to controls 
(N = 8) (ELS effect; p = 0.427). ACTH administration in control 
(N = 6) or ELS animals (N = 5) did not significantly affect fear 
learning (Figure 1A) and nor did dexamethasone administration 
in control (N = 4) or ELS animals (N = 3) (Figure 1A) (main 
effect of treatment; p =  0.575). Overall, all groups of animals 
learned the task in one session (main effect of tone; p < 0.001).
Twenty-four hours after the end of fear learning trials, fear 
extinction trials began. ELS rats had a significant deficit in 
fear extinction and exhibited freezing behavior significantly 
more frequently throughout the whole session than controls 
(Figure 1B; p < 0.0001). Although the vehicle-treated control 
animals exhibited clear extinction over the session, the vehicle-
treated ELS group had a moving score of 0.05 ±  0.02 by the 
30th tone, where a value of 1 would indicate moving during 
all measured time points after the tone and a value of 0 would 
indicate freezing during all measured time points after the tone. 
This demonstrates that ELS animals were unable to extinguish 
even at the end of the extinction session (Figure  1B). In 
addition, moving scores of vehicle-treated ELS animals were 
significantly different to vehicle-treated controls at the 30th 
tone (p < 0.001).
acTh improves Fear extinction  
in els animals
The rate of fear extinction is not altered with ACTH administra-
tion in control animals (p = 0.45; group by tone, vehicle-treated 
controls vs. ACTH-treated controls). However, importantly, 
the rate of extinction in ELS animals treated with ACTH is also 
indistinguishable from vehicle-treated controls (p = 0.15; group 
by tone, vehicle-treated controls vs. ACTH-treated ELS, see 
Figure 1B). This suggests that ACTH restores fear extinction in 
animals with a history of ELS. This is also reflected by comparison 
of moving scores at the end of the fear extinction session. At the 
30th tone, moving scores of ACTH-treated ELS animals were 
significantly higher than ELS animals (p = 0.006) and were not 
significantly different from vehicle-treated controls (p = 0.1).
acTh Does not ameliorate Water  
Maze Deficits
We have previously reported that the ELS paradigm significantly 
impairs hippocampal-dependent learning and memory. In order 
to determine whether or not treatment with ACTH was effective 
in ameliorating these deficits, we used a second cohort of ani-
mals that had experienced ELS with (N = 5) or without (N = 4) 
ACTH treatment from p6 to p16. Overall, all animals learned to 
find the platform, as seen by a significant effect of day (p < 0.001, 
Figure 2A). As previously reported, animals experiencing ELS 
have significant impairments during the Morris water maze 
(p =  0.01) in adulthood compared to controls (N =  6 treated 
with vehicle; N = 6 treated with ACTH). We found no change 
in water maze performance when animals were administered 
ACTH (p = 0.71) suggesting that treatment with ACTH does not 
improve hippocampal-dependent spatial cognition (Figure 2B).
Dexamethasone Does not improve  
Fear extinction in els animals
Early treatment with dexamethasone may actually worsen the rate 
of extinction for control animals (p = 0.003, group by tone effect 
comparing vehicle-treated to dexamethasone-treated controls), 
FigUre 1 | Fear conditioning after els and treatment with dexamethasone or acTh. Each panel represents a treatment condition, with the left panel 
depicting moving scores from vehicle-treated animals, the middle panel showing ACTH-treated animals, and the right panel dexamethasone-treated animals. All 
animals in all groups acquired the fear learning paradigm after three tone-shock pairings (a). However in (B), vehicle-treated ELS animals (red open circles, left 
panel) had significant deficits extinguishing the fear task compared to vehicle-treated controls (blue open circles, left panel), even after 30 tones without shock 
pairing. Treatment with ACTH (filled triangles, middle panel) did not alter fear extinction in control animals (blue) but significantly prevented fear extinction in animals 
with a history of ELS (red). Treatment with dexamethasone (stars) did not significantly improve fear extinction in animals with a history of ELS (red), even with the 
inclusion of one outlier animal representing two data points at tones 20 and 25 (shown as red Xs in the right panel).
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although the groups are not significantly different by the end of 
the extinction session (p = 0.07 at tone 30).
However, unlike ACTH, dexamethasone treatment in ELS 
animals does not restore fear extinction to the levels of vehicle-
treated controls as the rate of extinction was significantly different 
between the groups (p = 0.04; group by tone comparing vehicle 
control to dexamethasone-treated ELS). It is also worth noting 
that one animal in this group had outlier measurements at tone 20 
and tone 25 (shown as red Xs in panel 3 of Figure 1B); with these 
outliers removed, this effect is even more significant (p < 0.001). 
Indeed, dexamethasone treatment did not significantly improve 
the rate of fear extinction compared to vehicle-treated ELS 
FigUre 2 | els-associated deficits in water maze are not improved with acTh. Time-to-event (survival) analysis of the latency to find the platform in a 
Morris water maze task show that animals have a shorter latency to find the platform on day 4 (purple line) compared to day 1 (pink line). This indicates that, when 
adjusted for group, animals on average learn over the 4-day time course of the experiment (a). We then show in (B) that animals with a history of ELS have 
significant deficits in water maze (green line) over controls (blue line), seen as an increased proportion of animals having longer latencies to find the platform when 
day and trial are accounted for statistically. Treatment with ACTH during the time of the seizures does not improve this deficit (yellow line). Likewise, treatment with 
ACTH does not alter latency to find the platform in control animals (red line) as well.
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(p  =  0.39, group by tone comparing vehicle-treated ELS to 
dexamethasone-treated ELS). This is also true when comparing 
moving scores at the final tone (p = 0.966, group effect comparing 
vehicle-treated ELS to dexamethasone-treated ELS).
acTh and Dexamethasone Do not alter 
seizure latency or Duration
Having found that ACTH partially rescued the ability of ELS rats to 
extinguish fear, we then wanted to determine the effects of ACTH 
and dexamethasone administration on seizure properties in the 
flurothyl model of ELS. Overall, we found a significant reduction 
in latency and an increase in duration in both groups over day 
(main effect of day: p = 0.004 duration of seizure; p < 0.001 latency 
to seizure). There was no difference in the latency (Figure 3A) 
to or duration (Figure  3B) of flurothyl-induced seizures with 
administration of ACTH or dexamethasone; mean latency was 
116.47  ±  11.5  s in the vehicle-treated animals compared to 
106.29 ± 5.6 s in ACTH-treated animals and 119.16 ± 18.5 s in 
dexamethasone-treated animals (p = 0.63 group effect; p = 0.98 
group × day effect), mean duration was 80.24 ± 12.6 s in vehicle-
treated animals compared to 66.71  ±  4.9  s in ACTH-treated 
animals and 68.52 ±  7.8  s in dexamethasone-treated animals 
(p = 0.44 group effect; p = 0.27 group × day effect) (Figure 3).
els significantly reduce Mc3r and 
Mc4r expression in the PFc but  
not in ca1
As ACTH only improved the rate of fear extinction in animals with 
a history of ELS and dexamethasone did not, we wanted to deter-
mine whether the melanocortin receptor system of the CNS was 
altered after ELS. If central MCR system dysfunction was noted 
after ELS, this could point to a role of MCRs in the mechanism 
of action of ACTH in improving cognitive outcome. To address 
this question and confirm the presence of these receptors in these 
brain regions at this age, we stained and quantified cells express-
ing MC3R and MC4R in the infralimbic cortex of the mPFC and 
CA1 of the dorsal hippocampus in control and ELS animals at 
p19 (Figures 4A–F). In the infralimbic cortex, we found that the 
density (cell count/10,000 μm3) of cells expressing these MCRs 
was significantly lower in ELS animals than in controls across all 
layers (Figures 4A,B; p = 0.019 for MC3R; p = 0.001 for MC4R). 
However, the density of cells expressing MC3R or MC4R in the 
pyramidal cell layer of CA1 was not significantly different between 
groups (Figures 4C,D; p = 0.75 for MC3R; p = 0.33 for MC4R).
DiscUssiOn
Children with many different forms of epilepsy are significantly 
more likely to experience cognitive deficits consistent with frontal 
lobe dysfunction, including anxiety (25–28). Fear extinction is a 
reliable measure of prefrontal cognition in animal models (29, 30). 
Here, we show that rats with a history of ELS have significant 
deficits in fear extinction and spatial learning as adults, confirm-
ing that ELS animals have both hippocampal and prefrontal 
dysfunction. Additionally, we show that ACTH can prevent some 
of these cognitive deficits. This is the first time that the long-term 
cognitive impact of treatment with ACTH has been shown and 
suggests that add-on treatment with a melanocortin agonist 
during childhood seizures may lead to improvements in specific 
cognitive domains during adulthood. It is worth noting that the 
decision to use an ELS model instead of an infantile spasms model 
allows us to understand the generalizability of ACTH treatment 
for other forms of pediatric epilepsy as well.
FigUre 3 | seizure parameters are not altered by dexamethasone 
and acTh treatments. Treatment with dexamethasone (squares) or ACTH 
(triangles) does not alter latency to flurothyl seizure or latency to flurothyl 
seizure over the course of 4 days compared to vehicle-treatment (circles) (a). 
Likewise, treatment with dexamethasone or ACTH did not significantly alter 
seizure duration (B).
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Treatment with either ACTH or dexamethasone 1 h prior to 
seizures did not significantly reduce seizure duration or latency 
in our model; but interestingly ACTH, and not dexamethasone, 
was able to prevent deficits in fear extinction in the long term. 
This suggests that ACTH has an additional mechanism to its cor-
tisol-mediated effect, which could prevent deficits in prefrontal 
cognition. This also serves to challenge the notion that seizures 
themselves are solely responsible for cognitive deficits – a notion 
that pervades much of the literature as an unproven assumption. 
If ACTH does not alter seizure parameters and seizures were the 
sole cause of cognitive deficits, we would not expect ACTH to 
positively impact cognition, as shown both here and in a different 
seizure-related model (15), it does. To the best of our knowledge, 
only one other group has data to suggest that cognitive and seizure 
outcomes may be dissociable. In a model of prolonged febrile sei-
zure, decreased T2 signal in the whole brain is neuroprotective in 
terms of cognitive outcome (31), but decreased T2 signal in the 
amygdala is a biomarker for the development of future temporal 
lobe epilepsy (32). An improvement in cognitive outcome in the 
context of a negative seizure improvement outcome has never 
been evaluated in humans; our data presented here and the data 
of Baram’s group suggest that this may warrant further study.
An unexpected finding of our research was that ACTH was 
able to ameliorate cognitive deficits in PFC-dependent fear 
extinction, but it was unable to do so in hippocampal-dependent 
spatial learning. This difference in drug efficacy between the two 
tasks suggests that following ELS there may be something funda-
mentally different in the way these two brain regions respond that 
enables ACTH to protect one, but not the other. Quantification of 
MC3R- and MC4R-expressing cells reveals a correlation that may 
pose an explanation. Our results show that MC3R and MC4R are 
expressed in both the infralimbic cortex and in the CA1 of hip-
pocampus in control rats. However, following ELS, the density of 
cells expressing MC3R and/or MC4R was significantly decreased 
in the PFC compared to controls, but not significantly different 
in the CA1 between ELS rats and controls. As ACTH binds these 
receptors and was able to protect PFC cognition but not hip-
pocampal cognition, this suggests a role for central melanocortin 
signaling in this cognitive protection. We initially chose a time 
point of 36 h after the induction of the last seizure in order to 
assess the acute effect of the ELS insult on receptor expression. 
Our results show that MCRs are present in mPFC and CA1 at p19 
and are dysregulated by the ELS insult, thereby strengthening the 
hypothesis that ACTH acts via a CNS MCR-mediated mechanism 
to protect against injuries to prefrontal cognition. Important 
future directions include characterization of the effect of ACTH 
on the expression of MC3R and MC4R in rats with a history of 
ELS, and whether these differences in expression between control 
and ELS rats at p19 persist into later life.
ACTH, acting through MC2Rs in the adrenal cortex, leads to 
systemic release of glucocorticoid steroid hormones; and although 
glucocorticoid steroid hormones, such as dexamethasone, are 
able to modulate the formation, consolidation, and retrieval 
of fear memory acutely in adult controls (33), their long-term 
effect on pediatric patients with a history of seizures is unknown. 
The comparison of ACTH and dexamethasone in our study 
suggests that typical glucocorticoids would not have the same 
positive long-term impact on patients as ACTH, despite acute 
administration of glucocorticoids enhancing extinction in adults 
with phobias (34), and exogenous corticosterone administration 
facilitating fear extinction in mice (35). Indeed, an unexpected 
finding of the current study was the suggestion of a detrimental 
effect of dexamethasone on control rats. While the mechanism 
for this is unknown and not within the scope of the current study, 
it does indicate that the positive impact of ACTH on cognition is 
not entirely due to corticosteroid release. This also suggests that 
ACTH and not prednisone, another glucocorticoid drug given to 
patients that has some mineralocorticoid activity but no activity 
at melanocortin receptors, may be beneficial in improving cogni-
tive outcome. This result is not entirely unexpected, as there is 
some evidence that treatment with ACTH can improve cognitive 
outcomes in human patients with epilepsy. In a study done by 
Kivity and colleagues, children with cryptogenic infantile spasms 
normally associated with poor cognitive outcome were treated 
with high-dose ACTH. The authors note that early treatment 
was associated with a favorable long-term cognitive outcome 
FigUre 4 | Melanocortin receptor expression is downregulated in the PFc after els. In all layers of the mPFC, MC3 (a) and MC4 (B) receptors are 
significantly downregulated (p = 0.019 for MC3Rs; p = 0.001 for MC4Rs) in ELS animals (red bars) compared to control (blue bars). No significant group by layer 
effect was noted. No significant changes were noted in CA1 of the hippocampus in either MC3 (c) or MC4R (D) expression after ELS. Representative images of 
MC3R and MC4R staining in PFC are shown in (e), and MC3R and MC4R staining in CA1 are shown in (F) at 20× magnification. N = 8 control, N = 9 ELS.
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in all patients (10). In the UKISS study evaluating treatments 
for infantile spasms, children with no identified etiology and 
who received either ACTH or a corticosteroid, had significantly 
higher Vineland adaptive behavior scores at follow-up than 
children receiving vigabatrin (11). Interestingly, in parallel to 
our current study, no clear correlation between seizure freedom 
and outcome was established in the UKISS study. We show 
here for the first time a potential mechanism for this improve-
ment. Together, this research suggests that early diagnosis and 
treatment of pediatric epilepsies with ACTH may be of utmost 
importance to avoid some of the associated deleterious cognitive 
dysfunction.
Our results provide the first investigations of a potential 
mechanism underlying ACTH-related cognitive improvement 
after ELS, potentially implicating central melanocortin recep-
tors, MC3 and/or MC4R. Understanding the mechanism behind 
improved cognitive outcome has the potential to elucidate novel 
therapeutic targets for specifically directed add-on therapies for 
cognition in epilepsy. Additionally, the effectiveness of ACTH in 
improving cognitive outcome in our ELS model, instead of an 
infantile spasms model, suggests potential for generalizability of 
this putative novel therapeutic target beyond very severe epilep-
sies more broadly to pediatric epilepsy in general.
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